Pay in 4 interest-free payments of $6.83 Learn more
Ships within 48 hours · Estimated delivery Aug 13 - Aug 18
Liraglutide, one of the first GLP-1 approved by the FDA, was selected as the investigational therapy in this trial because of its extensive long-term efficacy and safety data in different patient populations
In everyday conversation, people often use Ozempic as shorthand for the whole GLP-1 weight-loss era, even though medications like Wegovy and Zepbound have their own approvals, dosing, and uses
VESPER-1: the durability signal In a 32-week exploratory extension (Part B) of VESPER-1, Pfizer reports a 15.9% non-placebo-adjusted weight loss with no plateau observed at 32 weeks on 2.4 mg weekly berobenatide in participants who escalated from placebo to active drug
QC-verified for identity and batch purity
US$ 24.17
US$ 24.57
US$ 28.14
US$ 27.31
